Top

BY Jill Russell, Ph.D.

A study published in JAMA comparing adverse event outcomes by treatment type for patients with localized prostate cancer reveals most functional differences diminish over time but differences in urinary incontinence and sexual function impairment persist through five years.  

“These findings are important because men consider the expected impact of treatment on urinary, sexual, bowel and hormonal function when selecting...

Patients with localized prostate cancer who underwent prostatectomy experienced worse urinary incontinence than those who received other treatment options.

BY Clayton Boldt

Prostate cancer is the most common cancer diagnosed in American men, and the second leading cause of cancer death in men. While hormone-based...

BY Ron Gilmore

Just as a driver’s night vision improves by simply cleaning the headlights, scientists at The University of Texas MD Anderson Cancer Center...

BY Clayton R. Boldt, Ph.D.

MD Anderson’s proteomics platform provides a valuable institutional resource, complete with state-of-the-art instruments and specialized expertise to help researchers analyze and understand thousands of cancer-related proteins. These proteins may be useful as therapeutic targets, early detection signals or biomarkers of cancer treatment response for a number of disease types, including lung, colon, breast, ovarian, pancreatic, prostate...

blood sample

BY MD Anderson staff

This is the second part of Cancer Frontline’s interview with Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology...

BY MD Anderson staff

In October 2018, the Nobel Prize in Physiology or Medicine was awarded to Jim Allison, Ph.D., chair of Immunology, for his discoveries on...

BY Clayton R. Boldt, Ph.D.

Excluding skin cancers, prostate cancer is the most commonly diagnosed cancer among men in the United States. According to the American Cancer...

BY Ron Gilmore

Reported online in the July 28 issue of Molecular Cell, a study conducted at MD Anderson has shown that a protein called ZMYND8 blocks expression...

BY Ron Gilmore

New findings about where and how aggressive forms of prostate cancer potentially begin may lead to new therapies for hard-to-treat and lethal...

BY Ron Gilmore

Immune suppressor cells called MDSCs (myeloid-derived suppressor cells) may be important in developing treatments for advanced prostate cancer...